Next Article in Journal
The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis
Next Article in Special Issue
Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1
Previous Article in Journal
Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature
Previous Article in Special Issue
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

1
Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK
2
Department of Pharmacy and Pharmacology, University of Bath, Bath BA1 1RL, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1269; https://doi.org/10.3390/ijms19051269
Received: 12 March 2018 / Revised: 10 April 2018 / Accepted: 18 April 2018 / Published: 24 April 2018
(This article belongs to the Special Issue Vascular Endothelial Growth Factor)
  |  
PDF [975 KB, uploaded 3 May 2018]
  |  

Abstract

Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease. View Full-Text
Keywords: interstitial lung disease; fibrosis; Vascular Endothelial Growth Factor; VEGF interstitial lung disease; fibrosis; Vascular Endothelial Growth Factor; VEGF
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Barratt, S.L.; Flower, V.A.; Pauling, J.D.; Millar, A.B. VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. Int. J. Mol. Sci. 2018, 19, 1269.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top